Exelixis (EXEL) Interest & Investment Income (2017 - 2026)
Exelixis (EXEL) posted quarterly Interest & Investment Income of $16.1 million for Q2 2026, down 15.46% year-over-year from $19.1 million in Q2 2025, and down 7.45% quarter-over-quarter from $17.4 million in Q1 2026.
Analysis
Exelixis (EXEL) Interest & Investment Income (2017 - 2026) Analysis & Trends
Exelixis' Interest & Investment Income history runs 10 years deep, the most recent figure standing at $16.1 million for Q2 2026.
- In Q2 2026, Interest & Investment Income fell 15.46% year-over-year to $16.1 million; the TTM figure through Apr 2026 stood at $66.3 million (down 13.2% YoY), while the FY2026 annual figure was $69.2 million, down 10.29% from the prior year.
- Interest & Investment Income for Q2 2026 stood at $16.1 million, down from $17.4 million in the prior quarter.
- The five-year high for Interest & Investment Income was $23.1 million in Q3 2023, with the low at $1.8 million in Q2 2022.
- The 5-year median for Interest & Investment Income is $17.4 million (2026), against an average of $16.6 million.
- Peak annual rise in Interest & Investment Income reached 1078.9% in 2022, while the deepest fall reached 32.07% in 2022.
- Exelixis' Interest & Investment Income stood at $17.0 million in 2022, then grew by 25.9% to $21.4 million in 2023, then retreated by 12.53% to $18.7 million in 2024, then declined by 14.9% to $15.9 million in 2025, then rose by 1.29% to $16.1 million in 2026.
- Business Quant data shows EXEL's Interest & Investment Income at $16.1 million in Q2 2026, $17.4 million in Q1 2026, and $15.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 14.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 14.21 Mn |
| Apr 3, 2026 | 16.13 Mn |
| Jan 2, 2026 | 17.43 Mn |
| Oct 3, 2025 | 15.92 Mn |
| Jul 4, 2025 | 16.79 Mn |
| Apr 4, 2025 | 19.08 Mn |
| Jan 3, 2025 | 21.30 Mn |
| Sep 27, 2024 | 18.71 Mn |
| Jun 28, 2024 | 17.26 Mn |
| Mar 29, 2024 | 19.89 Mn |
| Dec 29, 2023 | 21.39 Mn |
| Sep 29, 2023 | 23.11 Mn |
| Jun 30, 2023 | 22.54 Mn |
| Mar 31, 2023 | 19.50 Mn |
| Dec 30, 2022 | 16.99 Mn |
| Sep 30, 2022 | 9.50 Mn |
| Jul 1, 2022 | 4.76 Mn |
| Apr 1, 2022 | 1.82 Mn |
| Dec 31, 2021 | 1.44 Mn |
| Oct 1, 2021 | 1.66 Mn |